Cargando…
Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies
A major challenge in anticancer treatment is the pre-existence or emergence of resistance to therapy. AXL and MER are two members of the TAM (TYRO3-AXL-MER) family of receptor tyrosine kinases, which, when activated, can regulate tumor cell survival, proliferation, migration and invasion, angiogenes...
Autores principales: | Schoumacher, Marie, Burbridge, Mike |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332501/ https://www.ncbi.nlm.nih.gov/pubmed/28251492 http://dx.doi.org/10.1007/s11912-017-0579-4 |
Ejemplares similares
-
Naptumomab Estafenatox: Targeted Immunotherapy with a Novel Immunotoxin
por: Eisen, Tim, et al.
Publicado: (2014) -
Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
por: Tannir, Nizar M., et al.
Publicado: (2017) -
Statins as Potential Chemoprevention or Therapeutic Agents in Cancer: a Model for Evaluating Repurposed Drugs
por: Joharatnam-Hogan, Nalinie, et al.
Publicado: (2021) -
Chronodisruption and Ambulatory Circadian Monitoring in Cancer Patients: Beyond the Body Clock
por: Almaida-Pagan, Pedro F., et al.
Publicado: (2022) -
WEE1 Inhibitor: Clinical Development
por: Kong, Anthony, et al.
Publicado: (2021)